Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Marrow Supernatant Leptin as A Predictor of Chemotherapy Sensitivity in AML Patients

NCT07163728 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT07163728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07163728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Marrow Supernatant Leptin as A Predictor of Chemotherapy Sensitivity in AML Patients
Lead sponsor
Fujian Medical University Union Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2025
Completion date
December 31, 2026
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult, aml